A carregar...

CYP3A4-MEDIATED OXYGENATION VERSUS DEHYDROGENATION OF RALOXIFENE

Raloxifene was approved in 2007 by the FDA for the chemoprevention of breast cancer in postmenopausal women at high risk for invasive breast cancer. Approval was based in part on the improved safety profile for raloxifene relative to the standard treatment of tamoxifen. However, recent studies have...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Moore, Chad D., Reilly, Christopher A., Yost, Garold S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2887288/
https://ncbi.nlm.nih.gov/pubmed/20405834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/bi902213r
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!